, Cutaneous lymphomas appearing under biologics: 26 cases from the French Study Group on Cutaneous Lymphomas Running title: Cutaneous lymphomas appearing under biologics MANUSCRIPT COUNT: Abstract 250
, J-L Schmutz, vol.7, p.17
Dermatology department, AP-HP, Henri Mondor Hospital, INSERM U1053 Bordeaux Research in translational oncology, vol.3 ,
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project, Ann Rheum Dis, vol.76, pp.2025-2055, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01755566
The risk of lymphoma in patients with psoriasis, J Invest Dermatol, vol.126, pp.2194-201, 2006. ,
Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease, Clin Colorectal Cancer, 2017. ,
DOI : 10.1016/j.clcc.2017.06.009
URL : http://www.clinical-colorectal-cancer.com/article/S1533002817301524/pdf
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease, JAMA, vol.318, pp.1679-86, 2017. ,
Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk, Arch Dermatol, vol.146, pp.513-519, 2010. ,
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor alpha therapy, J Am Acad Dermatol, vol.78, pp.1068-1076, 2018. ,
Mycosis fungoides in the era of antitumour necrosis factor-?treatments, Br J Dermatol, vol.173, pp.590-593, 2015. ,
Mycosis fungoides with psoriasiform lesions, J Dermatol, vol.42, pp.227-236, 2015. ,
DOI : 10.1111/1346-8138.12749
A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris, Case Rep Dermatol, vol.1, issue.1, pp.60-65, 2009. ,
Mycosis fungoides in patients with psoriasis: an ongoing issue, Eur J Dermatol, vol.28, pp.235-236, 2018. ,
Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients, J Eur Acad Dermatol Venereol, vol.31, pp.1848-1852, 2017. ,
The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes, J Eur Acad Dermatol Venereol, vol.30, pp.31-33, 2016. ,
WHO-EORTC classification for cutaneous lymphomas, Blood, vol.105, issue.10, pp.3768-85, 2005. ,
DOI : 10.1182/blood-2004-09-3502
URL : https://air.unimi.it/bitstream/2434/566817/2/3768.full.pdf
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management, Am J Hematol, vol.92, issue.10, pp.1085-102, 2017. ,
DOI : 10.1002/ajh.24876
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24876
Occupational exposures and mycosis fungoides. A European multicentre case-control study (Europe). Cancer Causes Control CCC, vol.16, pp.1253-1262, 2005. ,
Environmental risk factors for mycosis fungoides, Curr Probl Dermatol, vol.35, pp.52-64, 2007. ,
Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome, Cancer Treat Rep, vol.63, issue.4, pp.591-597, 1979. ,
Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells, Hum Pathol, vol.34, issue.2, pp.119-148, 2003. ,
Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series, Cancer, vol.119, issue.4, pp.825-856, 2013. ,
DOI : 10.1002/cncr.27740
Cutaneous manifestations of methotrexate-associated lymphoproliferative disorders: report of two cases and a review of the literature, Acta Derm Venereol, vol.95, issue.3, pp.366-373, 2015. ,
Cutaneous EBV-related lymphoproliferative disorders, Semin Diagn Pathol, vol.34, issue.1, pp.60-75, 2017. ,
DOI : 10.1053/j.semdp.2016.11.003
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340146
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study, Br J Haematol, vol.98, issue.4, pp.927-960, 1997. ,
DOI : 10.1046/j.1365-2141.1997.3213138.x
Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma, J Cutan Pathol, vol.24, issue.8, pp.457-61, 1997. ,
Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.13, issue.8, pp.2146-53, 2013. ,
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma, Int J Dermatol, vol.56, issue.11, pp.1125-1134, 2017. ,
Mycosis fungoides associated with B-cell malignancies, Br J Dermatol, vol.155, issue.2, pp.379-86, 2006. ,
DOI : 10.1111/j.1365-2133.2006.07346.x
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer, Blood, vol.90, issue.1, pp.354-71, 1997. ,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2011. ,
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-90, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, vol.110, pp.1713-1735, 2007. ,
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, vol.110, pp.479-84, 2007. ,
Mycosis fungoides: the great imitator, J Am Acad Dermatol, vol.47, issue.6, pp.914-922, 2002. ,
Pilotropic cutaneous T-cell lymphoma without mucinosis. A variant of mycosis fungoides? French Study Group of Cutaneous Lymphomas, Arch Dermatol, vol.132, issue.6, pp.683-690, 1996. ,
DOI : 10.1001/archderm.1996.03890300111015
Folliculotropic mycosis fungoides: single-center study and systematic review, Arch Dermatol, vol.146, issue.6, pp.607-620, 2010. ,
Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment, Semin Cutan Med Surg, vol.37, issue.1, pp.11-18, 2018. ,
DOI : 10.12788/j.sder.2018.004
Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement, J Am Acad Dermatol, vol.70, issue.6, pp.993-1001, 2014. ,
DOI : 10.1016/j.jaad.2013.12.029
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects, J Cutan Pathol, vol.32, issue.10, pp.647-74, 2005. ,
DOI : 10.1111/j.0303-6987.2005.00495.x
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas, Blood, vol.95, issue.7, pp.2212-2220, 2000. ,
Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases, Blood, vol.119, issue.7, pp.1643-1652, 2012. ,
Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases, Br J Dermatol, vol.172, issue.6, pp.1547-54, 2015. ,
,
, CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome, J Invest Dermatol, vol.128, issue.2, pp.465-72, 2008.
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force, Eur J Cancer Oxf Engl, vol.93, pp.47-56, 1990. ,
T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings, Br J Dermatol, vol.153, issue.3, pp.565-73, 2005. ,
Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas, J Invest Dermatol, vol.117, issue.4, pp.920-926, 2001. ,
Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma, Blood, vol.96, issue.9, pp.2987-92, 2000. ,
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases, Am J Surg Pathol, vol.22, issue.10, pp.1192-202, 1998. ,
ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic largecell lymphoma, Blood, vol.118, issue.15, pp.4024-4059, 2011. ,
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases, Blood, vol.111, issue.2, pp.838-883, 2008. ,
Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy, Acta Derm Venereol, vol.97, issue.3, pp.358-64, 2017. ,
DOI : 10.2340/00015555-2543
URL : https://hal.archives-ouvertes.fr/hal-01516926
Primary cutaneous follicular helper T-cell lymphoma: a new subtype of cutaneous T-cell lymphoma reported in a series of 5 cases, Arch Dermatol, vol.148, issue.7, pp.832-841, 2012. ,
Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Case Series and Review of the Literature, Am J Dermatopathol, vol.39, issue.5, pp.374-83, 2017. ,
Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior, Am J Pathol, vol.155, issue.2, pp.483-92, 1999. ,
DOI : 10.1016/s0002-9440(10)65144-9
Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features, Histopathology, vol.67, issue.4, pp.425-466, 2015. ,
Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient, J Cutan Pathol, vol.43, issue.2, pp.125-161, 2016. ,
Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature, J Cutan Pathol, vol.38, issue.2, pp.209-224, 2011. ,
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas, Blood, 2008. ,
, Sep, vol.1, issue.5, pp.1600-1609
Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, issue.12, pp.1581-1588, 2007. ,
Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study, J Clin Oncol Off J Am Soc Clin Oncol, vol.19, issue.16, pp.3602-3612, 2001. ,
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases, Arch Dermatol, vol.143, issue.9, pp.1144-50, 2007. ,
MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma, J Invest Dermatol, vol.136, issue.8, pp.1741-1745, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01321411
Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients, J Am Acad Dermatol, vol.69, issue.3, pp.357-65, 2013. ,
Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas, Br J Dermatol, vol.166, issue.6, pp.1295-300, 2012. ,
Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders, Expert Opin Biol Ther, vol.17, issue.11, pp.1363-74, 2017. ,
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review, Pharmacol Ther, vol.117, issue.2, pp.244-79, 2008. ,
Treatment of rheumatoid arthritis with biological agents -as a typical and common immune-mediated inflammatory disease, Proc Jpn Acad Ser B Phys Biol Sci, vol.93, issue.8, pp.600-608, 2017. ,
Update on psoriasis immunopathogenesis and targeted immunotherapy, Semin Immunopathol, vol.38, pp.11-27, 2016. ,
DOI : 10.1007/s00281-015-0539-8
URL : http://europepmc.org/articles/pmc4706579?pdf=render
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies, Immune Netw, vol.17, issue.1, pp.25-40, 2017. ,
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis, vol.75, issue.3, pp.499-510, 2016. ,
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management, J Crohns Colitis, vol.11, issue.7, pp.769-84, 2017. ,
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, J Crohns Colitis, vol.11, issue.1, pp.3-25, 2017. ,
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis, vol.76, issue.6, pp.960-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01778213
Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial, J Am Acad Dermatol, 2018. ,
Emerging therapies in psoriasis: a systematic review, Cutis, vol.101, issue.3S, pp.5-9, 2018. ,
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study, Ann Rheum Dis, vol.76, issue.6, pp.1070-1077, 2017. ,
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study, Ann Rheum Dis, vol.76, issue.3, pp.571-92, 2017. ,
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension, Acta Derm Venereol, vol.98, issue.1, pp.98-102, 2018. ,
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nat Med, vol.21, issue.7, pp.719-748, 2015. ,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo-and active comparator-controlled VOYAGE 1 trial, J Am Acad Dermatol, vol.76, issue.3, pp.405-422, 2017. ,
Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials, Br J Dermatol, 2009. ,
Treating inflammation by blocking interleukin-1 in humans, Semin Immunol, vol.25, issue.6, pp.469-84, 2013. ,
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies, Bone Res, 2018. ,
, Anti-integrin therapy for inflammatory bowel disease, World J Gastroenterol, vol.6, issue.17, pp.1868-80, 2018.
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future, Dermatol Ther, 2018. ,
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician, Curr Rheumatol Rep, vol.19, issue.6, p.37, 2017. ,
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis, Nat Med, vol.5, issue.7, pp.828-859, 1999. ,
TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model, Br J Cancer, vol.90, issue.6, pp.1279-84, 2004. ,
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model, Exp Cell Res, vol.313, issue.11, pp.2345-55, 2007. ,
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, vol.295, pp.2275-85, 2006. ,
Adalimumab: longterm safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, Ann Rheum Dis, vol.72, issue.4, pp.517-541, 2013. ,
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data, Pharmacoepidemiol Drug Saf, vol.20, issue.2, pp.119-149, 2011. ,
Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials, J Rheumatol, vol.39, issue.4, pp.712-717, 2012. ,
Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-? antagonist therapy: a meta-analysis of randomized control trials, Asian Pac J Cancer Prev APJCP, vol.15, issue.8, pp.3403-3413, 2014. ,
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network metaanalysis. Cochrane Database Syst Rev, p.12183, 2016. ,
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, Ann Rheum Dis, vol.70, issue.11, pp.1895-904, 2011. ,
Association between tumor necrosis factor-? antagonists and risk of cancer in patients with inflammatory bowel disease, JAMA, vol.311, issue.23, pp.2406-2419, 2014. ,
Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis, Expert Opin Drug Saf, vol.15, issue.sup1, pp.35-54, 2016. ,
Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review, Br J Dermatol, 2017. ,
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of followup, Br J Dermatol, vol.168, issue.4, pp.844-54, 2013. ,
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-tosevere psoriasis: results from the PHOENIX 2 study through 5 years of follow-up, Br J Dermatol, vol.172, issue.5, pp.1371-83, 2015. ,
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study, Aliment Pharmacol Ther, vol.46, issue.3, pp.310-331, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01639670
An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors, J Eur Acad Dermatol Venereol JEADV, vol.29, issue.4, pp.752-60, 2015. ,
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden, BMJ, vol.346, p.1939, 2013. ,
Autocrine and paracrine regulation by cytokines and growth factors in melanoma, Cytokine, vol.12, issue.6, pp.547-54, 2000. ,
Serum TNF-?, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-?2b treatment of patients with melanoma, J Cancer Res Clin Oncol, vol.137, issue.3, pp.455-62, 2011. ,
Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?, J Surg Oncol, vol.109, issue.4, pp.338-385, 2014. ,
DOI : 10.1002/jso.23552
Isolated limb perfusion for melanoma intransit metastases: developments in recent years and the role of tumor necrosis factor alpha, Curr Opin Oncol, vol.23, issue.2, pp.183-191, 2011. ,
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers, Ann Rheum Dis, vol.76, issue.2, pp.386-91, 2017. ,
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry, J Am Acad Dermatol, vol.77, issue.5, pp.845-854, 2017. ,
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study), J Eur Acad Dermatol Venereol JEADV, 2018. ,
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab, RMD Open, vol.2, issue.1, p.213, 2016. ,
DOI : 10.1136/rmdopen-2015-000213
URL : https://rmdopen.bmj.com/content/rmdopen/2/1/e000213.full.pdf
Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice, Cancer Res, vol.63, issue.18, pp.5957-61, 2003. ,
Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonist. Jt Bone Spine Rev Rhum, vol.73, pp.333-337, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00465305
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry, Ann Rheum Dis, vol.69, issue.2, pp.400-408, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00456934
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project, Ann Rheum Dis, vol.76, issue.12, pp.2025-2055, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01755566
Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan, Mod Rheumatol, vol.26, issue.5, pp.642-50, 2016. ,
Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data, Rheumatol Oxf Engl, vol.53, issue.1, pp.186-94, 2014. ,
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-?) inhibitors: results of the REFURBISH study, Am J Gastroenterol, vol.108, issue.1, pp.99-105, 2013. ,
Safety of secukinumab in the treatment of psoriasis, Expert Opin Drug Saf, vol.15, issue.10, pp.1413-1433, 2016. ,
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis, J Am Acad Dermatol, vol.75, issue.1, pp.83-98, 2016. ,
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program, J Rheumatol, vol.40, issue.6, pp.787-97, 2013. ,
Assessing the safety of biologic agents in patients with rheumatoid arthritis, Rheumatol Oxf Engl, vol.51, issue.5, pp.38-47, 2012. ,
Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.369, issue.8, pp.699-710, 2013. ,
DOI : 10.1056/nejmoa1215734
Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.369, issue.8, pp.711-732, 2013. ,
DOI : 10.1056/nejmoa1215739
URL : https://serval.unil.ch/resource/serval:BIB_17E994FDC987.P001/REF.pdf
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers, Ann Rheum Dis, vol.76, issue.1, pp.105-116, 2017. ,
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, Ann Rheum Dis, vol.74, issue.3, pp.538-584, 2015. ,
Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis, Ann Rheum Dis, vol.76, issue.3, pp.497-503, 2017. ,
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis, JAMA, vol.308, issue.9, pp.898-908, 2012. ,
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials, Ann Rheum Dis, vol.74, issue.1, pp.96-103, 2015. ,
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, issue.8, pp.874-81, 2009. ,
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT TM Registry, Am J Gastroenterol, vol.109, issue.2, pp.212-235, 2014. ,
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study, Gastroenterology, vol.145, issue.5, pp.1007-1015, 2013. ,
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results, J Am Acad Dermatol, vol.72, issue.1, pp.115-137, 2015. ,
Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum, vol.37, pp.388-97, 2008. ,
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden, BMJ, vol.352, p.262, 2016. ,
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J Rheumatol, vol.32, issue.11, pp.2130-2135, 2005. ,
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia, J Natl Cancer Inst, vol.98, issue.18, pp.1321-1351, 2006. ,
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype, J Natl Cancer Inst, vol.98, issue.1, pp.51-60, 2006. ,
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis Rheum, vol.54, issue.3, pp.692-701, 2006. ,
Ankylosing Spondylitis, Psoriatic Arthritis, and Risk of Malignant Lymphoma: A Cohort Study Based on Nationwide Prospectively Recorded Data From Sweden. Arthritis Rheumatol, vol.66, pp.1282-90, 2014. ,
Long-term prognosis in patients with psoriasis, Br J Dermatol, vol.159, issue.2, pp.2-9, 2008. ,
Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.3, pp.36-46, 2013. ,
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study, J Invest Dermatol, vol.120, issue.2, pp.211-217, 2003. ,
The risk of melanoma and hematologic cancers in patients with psoriasis, J Am Acad Dermatol, vol.76, issue.4, pp.639-647, 2017. ,
The risk of malignancy associated with psoriasis, Arch Dermatol, vol.137, issue.6, pp.778-83, 2001. ,
The risk of lymphoma in patients with psoriasis, J Invest Dermatol, vol.126, issue.10, pp.2194-201, 2006. ,
Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis, J Invest Dermatol, vol.129, issue.11, pp.2604-2616, 2009. ,
Prevalence of skin and other cancers in patients with psoriasis, Clin Exp Dermatol, vol.18, issue.5, pp.401-405, 1993. ,
Lymphoma risk in psoriasis: results of the PUVA follow-up study, Arch Dermatol, vol.142, issue.9, pp.1132-1137, 2006. ,
Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom, Arch Dermatol, vol.139, issue.11, pp.1425-1434, 2003. ,
Psoriasis and risk of malignant lymphoma: a population-based cohort study, Br J Dermatol, 2017. ,
Viral infection, atopy and mycosis fungoides: a European multicentre case-control study, Eur J Cancer Oxf Engl, vol.39, issue.4, pp.511-517, 1990. ,
Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden, J Invest Dermatol, vol.117, issue.6, pp.1531-1538, 2001. ,
The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network, JAMA Dermatol, vol.152, issue.3, pp.282-90, 2016. ,
Inflammatory bowel disease, N Engl J Med, vol.347, issue.6, pp.417-446, 2002. ,
Ulcerative colitis and colorectal cancer. A population-based study, N Engl J Med, vol.323, issue.18, pp.1228-1261, 1990. ,
Risk of colorectal highgrade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease, Gastroenterology, vol.145, issue.1, pp.166-175, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00806654
The epidemiology of inflammatory bowel disease in Canada: a population-based study, Am J Gastroenterol, vol.101, issue.7, pp.1559-68, 2006. ,
Cancers Complicating Inflammatory Bowel Disease, N Engl J Med, vol.373, issue.2, p.195, 201509. ,
URL : https://hal.archives-ouvertes.fr/hal-01301711
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies, 148. van den Heuvel TRA, vol.19, pp.1270-80, 2013. ,
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.10, issue.6, pp.639-684, 2012. ,
Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis, vol.26, pp.31-41, 2006. ,
Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. Gastroenterol Clin North Am, vol.46, pp.515-544, 2017. ,
DOI : 10.1016/j.gtc.2017.05.006
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.8, issue.3, pp.268-74, 2010. ,
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease, Gastroenterology, vol.143, issue.2, pp.390-399, 2012. ,
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease, Inflamm Bowel Dis, vol.18, issue.11, pp.2063-71, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00683356
Risk of haematopoietic cancer in patients with inflammatory bowel disease, Gut, vol.54, issue.5, pp.617-639, 2005. ,
Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies, Am J Gastroenterol, vol.105, issue.7, pp.1480-1487, 2010. ,
Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III), J Crohns Colitis, vol.8, issue.1, pp.31-44, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00829286
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet Lond Engl, vol.374, issue.9701, pp.1617-1642, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00466312
Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle, Gut, vol.58, issue.10, pp.1427-1463, 2009. ,
DOI : 10.1136/gut.2009.181982
URL : https://hal.archives-ouvertes.fr/hal-00657979
Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease, Clin Colorectal Cancer, 2017. ,
DOI : 10.1016/j.clcc.2017.06.009
URL : http://www.clinical-colorectal-cancer.com/article/S1533002817301524/pdf
Malignancy and the Risks of Biologic Therapies: Current Status. Rheum Dis Clin North Am, vol.43, pp.43-64, 2017. ,
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer, JAMA Dermatol, vol.152, issue.2, pp.164-72, 2016. ,
Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, issue.11, pp.3909-3924, 2002. ,
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases, J Clin Oncol Off J Am Soc Clin Oncol, vol.14, issue.6, pp.1943-1952, 1996. ,
Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis, N Engl J Med, vol.328, issue.18, pp.1317-1338, 1993. ,
Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study ,
, Transpl Int Off J Eur Soc Organ Transplant, vol.13, issue.1, pp.388-393, 2000.
Cyclosporin-A associated malignancy, Clin Ophthalmol Auckl NZ, vol.1, issue.4, pp.421-451, 2007. ,
Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk, Arch Dermatol, vol.146, issue.5, pp.513-519, 2010. ,
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Gastroenterology, vol.141, issue.5, pp.1621-1628, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00631539
Hepatosplenic T cell lymphoma in inflammatory bowel disease, Gut, vol.57, issue.12, pp.1639-1680, 2008. ,
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease, JAMA, vol.318, issue.17, pp.1679-86, 2017. ,
Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy, J Drugs Dermatol JDD, vol.6, issue.8, pp.834-840, 2007. ,
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor alpha therapy, J Am Acad Dermatol, vol.78, pp.1068-1076, 2018. ,
DOI : 10.1016/j.jaad.2017.12.068
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials, J Am Acad Dermatol, vol.66, issue.5, pp.742-51, 2012. ,
Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases, J Eur Acad Dermatol Venereol JEADV, vol.23, issue.8, pp.967-975, 2009. ,
Mycosis fungoides in the era of antitumour necrosis factor-? treatments, Br J Dermatol, vol.173, issue.2, pp.590-593, 2015. ,
A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics, Indian J Dermatol, vol.62, issue.5, pp.533-538, 2017. ,
Aggressive cutaneous T-cell lymphomas after TNFalpha blockade, J Am Acad Dermatol, vol.51, issue.4, pp.660-662, 2004. ,
Mycosis fungoides-associated follicular mucinosis under adalimumab, Br J Dermatol, vol.153, issue.1, pp.207-215, 2005. ,
Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy, Clin Lymphoma Myeloma, vol.6, issue.4, pp.329-361, 2006. ,
Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy, J Am Acad Dermatol, vol.59, issue.5, pp.121-122, 2008. ,
Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept, Arch Dermatol, vol.145, issue.1, pp.94-99, 2009. ,
A case of mycosis fungoides with large cell transformation associated with infliximab treatment, Acta Derm Venereol, vol.94, issue.2, pp.233-237, 2014. ,
Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis, Br J Dermatol, vol.156, issue.4, pp.742-745, 2007. ,
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Res Ther, vol.7, issue.3, pp.666-676, 2005. ,
Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis, Dermatol Basel Switz, vol.225, issue.3, pp.259-63, 2012. ,
Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep, vol.1, pp.56-65, 2015. ,
CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab, Br J Dermatol, vol.149, issue.1, pp.170-173, 2003. ,
Lymphomatoid papulosis in a patient with Crohn's disease treated with infliximab, Inflamm Bowel Dis, vol.15, issue.7, pp.965-971, 2009. ,
Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab, J Am Acad Dermatol, vol.71, issue.3, pp.86-87, 2014. ,
Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis, Acta Derm Venereol, vol.89, issue.6, pp.653-657, 2009. ,
Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis, Br J Dermatol, vol.160, issue.4, pp.889-90, 2009. ,
Adult T-cell leukemia/lymphoma triggered by adalimumab, J Clin Virol Off Publ Pan Am Soc Clin Virol, vol.58, issue.2, pp.494-500, 2013. ,
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.12, pp.2046-54, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02051025
Psoriasiform mycosis fungoides masquerading as tumourous plaques, Eur J Dermatol EJD, vol.27, issue.3, pp.295-301, 201701. ,
Mycosis fungoides with psoriasiform lesions, J Dermatol, vol.42, issue.2, pp.227-236, 2015. ,
A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris. Case Rep Dermatol, vol.1, pp.60-65, 2009. ,
Defining early mycosis fungoides, J Am Acad Dermatol, vol.53, issue.6, pp.1053-63, 2005. ,
The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes, J Eur Acad Dermatol Venereol JEADV, vol.30, issue.10, pp.31-33, 2016. ,
Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients, J Eur Acad Dermatol Venereol JEADV, 2017. ,
The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome, Br J Dermatol, vol.148, issue.4, pp.709-727, 2003. ,
Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway, J Invest Dermatol, vol.131, issue.6, pp.1331-1339, 2011. ,
CD30 and type 2 T helper (Th2) responses, J Leukoc Biol, vol.57, issue.5, pp.726-756, 1995. ,
Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study, Blood, vol.102, issue.3, pp.1042-50, 2003. ,
Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity, PLoS ONE, vol.7, issue.12, 2009. ,
Unmasking mycosis fungoides/Sézary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course, Br J Dermatol, vol.174, issue.4, pp.901-905, 2016. ,
, Coexistence d'un mycosis fongoïde (haut) T1aN0M0 et d'une lymphoprolifération T CD30+ (bas) (Dr Franck), vol.4
, Mycosis fongoïde T2N0M0, vol.5
, Photographies prises avant et après la biothérapie, où les lésions de mycosis fongoïde sont démasquées, Mycosis fongoïde T2N0M0, vol.7
, Mycosis fongoïde T2N0M0, vol.9
, Papulose lymphomatoïde T1N0M0, vol.16
, LSCT type panniculite ?? T2bN0M0, vol.19
, Lymphome cutané B centro-folliculaire T1N0M0 (Dr Franck), Patient, vol.20
, Background: Controversies exist regarding the primary cutaneous lymphomas (PCL) risk under biologics, their prognosis and management. Most cases reported occurred under TNF? inhibitors. Our objective was to describe PCL occurring under biologics, type, behavior and management, Lymphome cutané B centro-folliculaire T1N0M0 (Dr Adamski), vol.21
, Retrospective, multicenter declarative (exhaustive data collection sheet) study among the 8364 patients registered from 2010 to 2017 into the French Cutaneous Lymphoma Study Group (GFELC), Main biologic: anti-TNF? (n=40)
Mean onset: 32 months; 24 mycosis fungoides (MF), including 5 transformed-MF (T-MF) with aggressive behavior. For all T-MF but one, psoriasis was the disease justifying biologics. After CTCL diagnosis, biologic was discontinued in all except 3 patients (n=2 Crohn disease and n=1 rheumatoid arthritis) with limited MF, stage ? IIA, cases (70%) including 15 with past dermatological history, p.31 ,
13 cases (30%) including 2 with past dermatological history. Mean onset: 69 months. Most were indolent forms with good prognosis ,
, Biologic's aggravating role may be suspected in two situations: pre-existing MF misdiagnosed as psoriasis (aggressive behavior) and psoriasis-associated MF. However, PCL (MF or not MF) might occur outside of psoriasis, with a variable course. In limited MF, biologics may be continued with close follow-up if the underlying disease justifies it. Recurrence of CBCL when biologic was re-introduced or continued
, Cutaneous lymphomas appearing under biologics : Retrospective multicentric study among the French Study Group on Cutaneous Lymphomas. Additional analysis from the National Pharmacovigilance Database